Buscar
Rallybio Corp
RLYBAñadir a la lista de seguimiento
15.815USD
-0.125-0.78%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
82.90MCap. mercado
PérdidaP/E TTM
Más Datos de Rallybio Corp Compañía
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
Información de Rallybio Corp
Símbolo de cotizaciónRLYB
Nombre de la empresaRallybio Corp
Fecha de salida a bolsaJul 29, 2021
Director ejecutivoUden (Stephen)
Número de empleados25
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 29
Dirección234 Church Street
CiudadNEW HAVEN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal06510
Teléfono12038593820
Sitio Webhttps://rallybio.com/
Símbolo de cotizaciónRLYB
Fecha de salida a bolsaJul 29, 2021
Director ejecutivoUden (Stephen)
Ejecutivos de Rallybio Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Stephen (Steve) Uden, M.D.
Dr. Stephen (Steve) Uden, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
92.54K
+0.67%
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
4.12K
-0.02%
Ms. Paula Soteropoulos
Ms. Paula Soteropoulos
Independent Director
Independent Director
2.98K
-0.10%
Dr. Steven W. Ryder, M.D.
Dr. Steven W. Ryder, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Dr. Robert (Rob) Hopfner, Ph.D.
Dr. Robert (Rob) Hopfner, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ronald M. (Ron) Hunt
Mr. Ronald M. (Ron) Hunt
Independent Director
Independent Director
--
--
Dr. Lucian Iancovici, M.D.
Dr. Lucian Iancovici, M.D.
Independent Director
Independent Director
--
--
Ms. Christine A. Nash
Ms. Christine A. Nash
Independent Director
Independent Director
--
--
Dr. Hui Liu, Ph.D.
Dr. Hui Liu, Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Stephen (Steve) Uden, M.D.
Dr. Stephen (Steve) Uden, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
92.54K
+0.67%
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
4.12K
-0.02%
Ms. Paula Soteropoulos
Ms. Paula Soteropoulos
Independent Director
Independent Director
2.98K
-0.10%
Dr. Steven W. Ryder, M.D.
Dr. Steven W. Ryder, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Dr. Robert (Rob) Hopfner, Ph.D.
Dr. Robert (Rob) Hopfner, Ph.D.
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Rallybio Corp?
Los cinco principales accionistas de Rallybio Corp son: Dr. Stephen (Steve) Uden, M.D.
¿Cuántas instituciones poseen acciones de Rallybio Corp (RLYB)?
A fecha de 2026Q1, 138 instituciones poseen acciones de Rallybio Corp, con un valor de mercado combinado de aproximadamente 3.48M, lo que representa el 65.82% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -412366.00.